Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986618000022/alxn10k12312017.htm
July 2021
July 2021
May 2021
May 2021
April 2021
March 2021
February 2021
February 2021
January 2021
December 2020
• | 2017 Total Revenues of $3.551 Billion, a 15 Percent Increase Over 2016 and a 17 Percent Volume Increase |
• | 2017 GAAP Diluted EPS of $1.97 Per Share, a 12 Percent Increase Over 2016; Non-GAAP Diluted EPS of $5.86 Per Share, a 27 Percent Increase Over 2016 |
• | Continued Double-Digit Volume Growth of Soliris in 2017 Despite Rapid Enrollment in ALXN1210 Trials |
• | Initial Launches Underway for Soliris in Patients with AchR Antibody-Positive Generalized Myasthenia Gravis (gMG) in the U.S., Germany and Japan |
• | Data from ALXN1210 Phase 3 PNH Naive and Switch Studies Expected in Second Quarter of 2018 |
• | Four New Independent Directors With Deep Biopharmaceutical Experience Appointed to Alexion's Board of Directors |
• | 2018 Guidance: Revenue $3.850 to $3.950 Billion; GAAP Diluted EPS $4.35 to $4.75 Per Share; Non-GAAP Diluted EPS $6.60 to $6.80 Per Share |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986618000022/alxn10k12312017.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Rating
Learn More![]()
We expect increases in cash flows from operations which will be highly dependent on sales levels, and the related cash collections from sales of our products.
The increase was driven by an increase in gross margin on product sales of
in direct product development expenses related primarily to an increase in costs associated with the manufacturing of material for ALXN1210 and ALXN6000 clinical research activities.
in direct product development expenses related primarily to an increase in costs associated with the manufacturing of material for increased clinical research activities and clinical studies.
of deferred tax expense we recognized in 2016 attributable to first quarter distributions from our foreign captive partnership, which increased our 2016 effective tax rate by 20.7%.
Subsequent adjustments for further declines...Read more
The 2017 Plan replaced the...Read more
is primarily attributable to the...Read more
related to decreases to our...Read more
The Tax Act decreased the...Read more
Partially offsetting these increases was...Read more
Our selling, general and administrative...Read more
On a periodic basis, as...Read more
If our estimate of the...Read more
We enter into foreign exchange...Read more
This increase includes a transition...Read more
The increase was also attributable...Read more
The new standard provides a...Read more
The Tax Act resulted in...Read more
Additionally, the value of the...Read more
With the consent of the...Read more
We record the effective portion...Read more
We have recorded goodwill, acquired...Read more
The increase in cash used...Read more
The stated objectives of our...Read more
increase was primarily due to...Read more
In February 2017, our Board...Read more
, acquisition-related costs associated with...Read more
Clinical development costs are comprised...Read more
When identifiable intangible assets, including...Read more
One aspect of the standard...Read more
Under the 2017 Plan, restricted...Read more
will be recorded in net...Read more
We expect our research and...Read more
In March 2013, we received...Read more
drug product associated with clinical...Read more
The components of this increase...Read more
The timing and level of...Read more
Other R&D expenses consist of...Read more
increased sales of Strensiq and...Read more
support personnel expenses and other...Read more
This standard is effective for...Read more
The standard is effective for...Read more
The standard is effective for...Read more
The standard is effective for...Read more
The standard is effective for...Read more
Amortization expense is primarily associated...Read more
Amortization expense associated with purchased...Read more
due to increased demand globally...Read more
The increase in interest expense...Read more
We expect our selling, general...Read more
For additional information related to...Read more
During 2017, we also had...Read more
Increase in external selling, general...Read more
Conclusion of the IRS examination...Read more
We expect our operating expenses...Read more
The plan is expected to...Read more
Direct expenses are comprised of...Read more
The purchase price of common...Read more
We operate in certain jurisdictions...Read more
Equity investments with readily determinable...Read more
was primarily due to an...Read more
The increase in net product...Read more
In February 2016, the FASB...Read more
in unit volumes is due...Read more
The decrease in the effective...Read more
We manage our foreign currency...Read more
The determination of whether or...Read more
The components of this increase...Read more
These increases were primarily due...Read more
Intangible assets related to IPR&D...Read more
In addition, we recorded an...Read more
Contingent payments associated with these...Read more
We have financed our operations...Read more
in the effective tax rate...Read more
and an effective tax rate...Read more
and an effective tax rate...Read more
Amortization of purchased intangible assets...Read more
Amortization of Purchased Intangible Assets...Read more
Due to the early stage...Read more
Due to the early stage...Read more
Due to the early stage...Read more
Salary, benefits and other labor...Read more
We recorded a gain in...Read more
Accordingly, the landlords costs of...Read more
Accordingly, the landlords costs of...Read more
Accordingly, the landlords costs of...Read more
Licensing agreement costs include upfront...Read more
We record estimated rebates payable...Read more
The assumptions related to determining...Read more
The purchase agreements for our...Read more
The new standard is intended...Read more
in facilities and other expenses...Read more
We cannot guarantee that results...Read more
Employee related costs associated with...Read more
Borrowings under the term loan...Read more
Borrowings under the term loan...Read more
The plan is expected to...Read more
The increase was primarily related...Read more
The increase was primarily related...Read more
Accordingly, the landlords costs of...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-18-000022
Submitted to the SEC: Thu Feb 08 2018 4:26:33 PM EST
Accepted by the SEC: Thu Feb 08 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations